|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
OLC190645356X |
| 003 |
DE-627 |
| 005 |
20230518100911.0 |
| 007 |
tu |
| 008 |
121107s2012 xx ||||| 00| ||und c |
| 028 |
5 |
2 |
|a sw121106_1
|
| 035 |
|
|
|a (DE-627)OLC190645356X
|
| 035 |
|
|
|a (DE-599)GBVOLC190645356X
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 082 |
0 |
4 |
|a 610
|
| 084 |
|
|
|a PHARM
|2 fid
|
| 084 |
|
|
|a XA 52835
|q AVZ
|2 rvk
|
| 084 |
|
|
|a 44.38
|2 bkl
|
| 084 |
|
|
|a 44.40
|2 bkl
|
| 100 |
1 |
|
|a Jauslin, Petra
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Identification of the Mechanism of Action of a Glucokinase Activator From Oral Glucose Tolerance Test Data in Type 2 Diabetic Patients Based on an Integrated Glucose-Insulin Model
|
| 264 |
|
1 |
|c 2012
|
| 300 |
|
|
|a 11
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 700 |
1 |
|
|a Karlsson, Mats
|4 oth
|
| 700 |
1 |
|
|a Frey, Nicolas
|4 oth
|
| 773 |
0 |
8 |
|i Enthalten in
|t The journal of clinical pharmacology
|d Thousand Oaks, Calif. : Sage Science Press, 1973
|g 52(2012), 12 vom: Dez., Seite 1861-1872
|w (DE-627)129413534
|w (DE-600)188980-1
|w (DE-576)014792656
|x 0091-2700
|7 nnns
|
| 773 |
1 |
8 |
|g volume:52
|g year:2012
|g number:12
|g month:12
|g pages:1861-1872
|g extent:11
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_OLC
|
| 912 |
|
|
|a FID-PHARM
|
| 912 |
|
|
|a SSG-OLC-PHA
|
| 912 |
|
|
|a SSG-OLC-DE-84
|
| 912 |
|
|
|a SSG-OPC-PHA
|
| 912 |
|
|
|a GBV_ILN_20
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_65
|
| 912 |
|
|
|a GBV_ILN_2006
|
| 912 |
|
|
|a GBV_ILN_4012
|
| 912 |
|
|
|a GBV_ILN_4112
|
| 912 |
|
|
|a GBV_ILN_4219
|
| 912 |
|
|
|a GBV_ILN_4305
|
| 936 |
r |
v |
|a XA 52835
|
| 936 |
b |
k |
|a 44.38
|q AVZ
|
| 936 |
b |
k |
|a 44.40
|q AVZ
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 52
|j 2012
|e 12
|c 12
|h 1861-1872
|g 11
|
